Birchview Capital, LP Cytokinetics Inc Transaction History
Birchview Capital, LP
- $95 Million
- Q2 2025
A detailed history of Birchview Capital, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Birchview Capital, LP holds 10,000 shares of CYTK stock, worth $593,500. This represents 0.35% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$593,500
Previous $401,000
17.71%
% of portfolio
0.35%
Previous 0.36%
Shares
7 transactions
Others Institutions Holding CYTK
# of Institutions
383Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.04 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$871 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$711 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$465 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$378 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.59B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...